Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762124 | 0.98 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNATHRBKMT2A | |
| SCHEMBL13419656 | 0.95 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNATHRBKMT2A | |
| SCHEMBL4256274 | 0.89 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAKMT2AWDR5 | |
| SCHEMBL4296358 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNATHRBKMT2A | |
| SCHEMBL24628490 | 0.84 | PDE10A (0.45) | MAPTPDE10A | |
| SCHEMBL31485219 | 0.84 | PDE10A (0.43) | ALDH1A1MAPTHTTSLC6A5SMN1; SMN2 | |
| SCHEMBL29772858 | 0.84 | PDE10A (0.45) | MAPTPDE10A | |
| SCHEMBL4288048 | 0.84 | PDE10A (0.43) | ALDH1A1MAPTLMNASMN1; SMN2TDP1 | |
| SCHEMBL29772884 | 0.84 | PDE10A (0.45) | MAPTPDE10A | |
| SCHEMBL4294688 | 0.84 | PDE10A (0.43) | ALDH1A1MAPTLMNASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | ALDH1A1 1961/4885MAPT 4710/4885LMNA 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.